Health and economic outcomes of HPV 16,18 vaccination in 72 GAVI-eligible countries

Vaccine

Volumn 26, Issue 32, 2008, Pages 4080-4093

  Goldie, Sue J ^a   O'Shea, Meredith ^a   Campos, Nicole Gastineau ^a   Diaz, Mireia ^a,b,c   Sweet, Steven ^a   Kim, Sun Young ^a  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^c UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

Cost effectiveness; GAVI; HPV

Indexed keywords

ROTAVIRUS VACCINE; WART VIRUS VACCINE;

ARTICLE; CANCER RISK; COST EFFECTIVENESS ANALYSIS; DEVELOPING COUNTRY; DISABILITY; FEMALE; GHANA; HEALTH CARE COST; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; IMMUNIZATION; INDIA; KENYA; NIGERIA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; UGANDA; UTERINE CERVIX CANCER;

ADOLESCENT; ADULT; DEVELOPING COUNTRIES; FEMALE; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMANS; MODELS, ECONOMIC; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; REPRODUCIBILITY OF RESULTS; UTERINE CERVICAL NEOPLASMS; VACCINATION;

EID: 47149105449     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2008.04.053     Document Type: Article

References (48)

1. World Health Organization (WHO). Projections of mortality and burden of disease. Available at http://www.who.int/healthinfo/statistics/bodprojections2030/en/index.html [accessed on January 29, 2008].
2. Munoz N., Castellsague X., de Gonzalez A.B., and Gissmann L. HPV in the etiology of human cancer. Vaccine 24 Suppl 3 (2006) S1-S10 [Chapter 1]
3. Munoz N., Bosch F.X., Castellsague X., Diaz M., De Sanjose S., Hammouda D., et al. Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int J Cancer 111 (2004) 278-285
4. Smith J.S., Lindsay L., Hoots B., Keys J., Franceschi S., Winer R., et al. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer 121 (2007) 621-632
5. Parkin D.M., and Bray F. The burden of HPV-related cancers. Vaccine 24 Suppl 3 (2006) S11-S25 [Chapter 2]
6. Denny L., Quinn M., and Sankaranarayanan R. Screening for cervical cancer in developing countries. Vaccine 24 Suppl 3 (2006) S71-S77 [Chapter 8]
7. Future II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 356 (2007) 1915-1927
8. Ault K.A., and Future II Study Group. Effect of prophylactic human papillomavirus L1 virus-like particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials. Lancet 369 (2007) 1861-1868
9. Garland S.M., Hernandez-Avila M., Wheeler C.M., Perez G., Harper D.M., Leodolter S., et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 356 (2007) 1928-1943
10. Harper D.M., Franco E.L., Wheeler C.M., Moscicki A.B., Romanowski B., Roteli-Martins C.M., et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 367 (2006) 1247-1255
11. Paavonen J., Jenkins D., Bosch F.X., Naud P., Salmeron J., Wheeler C.M., et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 369 (2007) 2161-2170
12. GAVI Alliance. Available at http://www.gavialliance.org/ [accessed on April 13, 2008].
13. Kim S., Salomon J.A., and Goldie S.J. Economic evaluation of hepatitis B vaccination in low-income countries: using cost-effectiveness affordability curves. Bull World Health Organ 85 11 (2007) 833-842
14. Goldie S.J., Kim J.J., Kobus K., Goldhaber-Fiebert J.D., Salomon J., O'Shea M.K.H., et al. Cost-effectiveness of HPV 16, 18 vaccination in Brazil. Vaccine 25 (2007) 6257-6270
15. Disease Control Priorities Project (DCPP). Available at http://www.dcp2.org/main/Home.html [accessed on January 28, 2008].
16. In: Drummond M.F., Sculpher M.J., Torrance G.W., O'Brien B.J., and Stoddart G.L. (Eds). Methods for the economic evaluation of health care programs. 3rd edition (2005), Oxford University Press, New York, NY
17. In: Gold M.R., Siegel J.E., Russell L.B., and Weinstein M.C. (Eds). Cost-effectiveness in health and medicine (1996), Oxford University Press, New York, NY
18. World Health Organization (WHO) Statistical Information System. CHOICE (CHOosing Interventions that are Cost Effective). Available at http://www.who.int/choice/en/ [accessed on January 29, 2008].
19. Kim J.J., Kuntz K.M., Stout N.K., Mahmud S., Villa L.L., Franco E.L., et al. Multi-parameter calibration of a natural history model of cervical cancer. Am J Epidemiol 166 (2007) 137-150
20. Kim J.J., Andres-Beck B., and Goldie S.J. The value of including boys in an HPV vaccination programme: a cost-effectiveness analysis in a low-resource setting. Br J Cancer 97 9 (2007) 1322-1328
21. United Nations (UN), Department of Economic and Social Affairs, Population Division. World population prospects: The 2004 revision. CD-ROM Edition-Extended Dataset; 2005 [United Nations publications, Sales No. E.05.XIII.12].
22. Murray C.J.L., and Lopez A.D. Estimating causes of death: new methods and global and regional applications for 1990. In: Murray C.J.L., and Lopez A.D. (Eds). The global burden of disease, vol. 1 of Global burden of disease and injury series (1996), Harvard University Press, Cambridge, MA 117-200
23. World Health Organization (WHO). The World Health Report 2002: list of Member States by WHO region and mortality stratum; 2002. Available at http://www.who.int/whr/2002/MembersETC.pdf [accessed on January 29, 2008].
24. World Health Organization (WHO). Life tables for WHO member states; 2004. Available at http://www.who.int/whosis/database/life_tables/life_tables.cfm [accessed on January 29, 2008].
25. Parkin DM, Whelan SL, Ferlay J, Storm H. Cancer incidence in five continents, vol. I-VIII. IARC CancerBase No. 7. Lyon; 2005.
26. Parkin DM, Ferlay J, Hamdi-Chérif M, Sitas F, Thomas JO, Wabinga H, Whelan SL (Eds.). Cancer in Africa: epidemiology and prevention, IARC Scientific Publications No. 153. Lyon: IARC; 2003.
27. Ferlay J., Bray F., Pisani P., and Parkin D.M. GLOBOCAN 2002. Cancer incidence, mortality and prevalence worldwide. IARC Cancer Base No. 5 Version 2.0 (2004), IARC Press, Lyon, France
28. Diaz Sanchis M., Kim J.J., Albero G., de Sanjose S., Clifford G., Bosch F.X., et al. Health and economic impact of HPV 16 and 18 vaccination and cervical cancer screening in Southeastern India [Podium presentation: 6B-01]. Proceedings of the 24th international papillomavirus conference and clinical workshop. Beijing, China, November 3-9 (2007)
29. Kim J.J., Kobus K.E., O'Shea M., and Goldie S.J. Impact of HPV vaccine duration and efficacy on cost-effectiveness of vaccination in Vietnam [Abstract: PS19-35]. Proceedings of the 24th International Papillomavirus Conference and Clinical Workshop. Beijing, China, November 3-9 (2007)
30. Kim J.J., Kobus K.E., Diaz-Sanchis M., O'Shea M., and Goldie S.J. Cost-effectiveness of cervical cancer prevention policy in Vietnam [Abstract: PS19-34]. Proceedings of the 24th International Papillomavirus Conference and Clinical Workshop. Beijing, China, November 3-9 (2007)
31. Wolfson L.J., Gasse F., Lee-Martin S.P., Lydon P., Magan A., Tibouti A., et al. Estimating the costs of achieving the WHO-UNICEF Global Immunization Vision and Strategy, 2006-2015. Bull World Health Organ 86 (2008) 27-39
32. World Bank. World Development Indicators (WDI) Online. Available at http://go.worldbank.org/6HAYAHG8H0 [accessed on January 29, 2008].
33. Acharya A., Diaz-Ortega J.L., Tambini G., de Quadros C., and Arita I. Cost-effectiveness of measles elimination in Latin America and the Caribbean: a prospective analysis. Vaccine 20 27-28 (2002) 3332-3341
34. Kou U. Guidelines for estimating costs of introducing new vaccines into the national immunization system. (2002), World Health Organization, Department of Vaccines and Biologicals, Geneva
35. Walker D., Mosqueira N.R., Penny M.E., Lanata C.F., Clark A.D., Sanderson C.F., et al. Variation in the costs of delivering routine immunization services in Peru. Bull World Health Organ 82 9 (2004) 676-682
36. Miller M.A., and McCann L. Policy analysis of the use of hepatitis b, haemophilus influenzae type b, streptococcus pneumoniae-conjugate and rotavirus vaccines in national immunization schedules. Health Econ 9 (2000) 19-35
37. Waters H.R., Dougherty L., Simon-Pierce T., Tran N., Wysonge C.S., Long K., et al. Coverage and costs of childhood immunizations in Cameroon. Bull World Health Organ 82 9 (2004) 668-675
38. Goldie S.J., Gaffikin L., Goldhaber-Fiebert J.D., Gordillo-Tobar A., Levin C., Wright T.C., et al. Cost-effectiveness of cervical cancer screening in five developing countries. N Engl J Med 353 20 (2005) 2158-2168
39. Goldhaber-Fiebert J.D., and Goldie S.J. Estimating the cost of cervical cancer screening in five developing countries. Cost Effect Resour Alloc 4 (2006) 13
40. World Health Organization. Macroeconomics and health: investing in health for economic development: report of the commission on macroeconomics and health (2001), World Health Organization, Geneva
41. Bloom D.E., Canning C., and Weston M. The value of vaccination. World Econ 6 (2005) 15-39
42. UNICEF/WHO. Global immunization vision and strategy (GIVS): strategic framework for 2006-2015. Geneva: UNICEF/WHO; October 2005. Available at: http://www.who.int/vaccines-documents/DocsPDF05/GIVS_Final_EN.pdf [accessed on January 29, 2008].
43. Bilous J, Eggers R, Gasse F, Jarrett S, Lydon P, Magan A, et al. A new global immunisation vision and strategy. Lancet 2006; 367:1464-6. PMID:16679143; doi:10.1016/S0140-6736(06)68625-X10.1016/S0140-6736(06)68625-X.
44. Khan MM and Yoder RA. Expanded Program on Immunization in Bangladesh: cost, cost-effectiveness, and financing estimates, Technical Report No. 24. Bethesda, MD: Partnerships for Health Reform Project, Abt Associates Inc.; September 1998.
45. Kaddar M, Mookherji S, DeRoeck D, Antona D. Case Study on the costs and financing of immunization services in Morocco. Special Initiatives Report No. 18. Bethesda, MD: Partnerships for Health Reform Project, Abt Associates Inc.; September 1999.
46. Levin A., England S., Jorissen J., Garshong B., and Teprey J. Case study on the costs and financing of immunization services in Ghana (September 2001), The Partners for Health Reformplus Project, Abt Associates Inc., Bethesda, MD
47. IAVI/PATH. HPV vaccine adoption in developing countries: cost and financing issues. Proceedings of the 2007 International AIDS Vaccine Initiative/Program for Appropriate Technology in Health (PATH). Available at http://www.iavi.org/viewfile.cfm?fid=47496 [Accessed on February 29, 2008].
48. Islam MK. The costs of maternal-newborn illness and mortality. Series: Moving towards universal coverage: issues in maternal-newborn health and poverty. World Health Organization; 2006. Available at: http://www.who.int/reproductive-health/universal_coverage/issue2/costsmnh_gerdtham2.pdf [accessed on April 13, 2008].